103 related articles for article (PubMed ID: 29941390)
1. BRCAness Combined With a Family History of Cancer Is Associated With a Poor Prognosis for Breast Cancer Patients With a High Risk of BRCA Mutations.
Mori H; Kubo M; Kai M; Velasquez VV; Kurata K; Yamada M; Okido M; Kuroki S; Oda Y; Nakamura M
Clin Breast Cancer; 2018 Oct; 18(5):e1217-e1227. PubMed ID: 29941390
[TBL] [Abstract][Full Text] [Related]
2. BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer.
Mori H; Kubo M; Nishimura R; Osako T; Arima N; Okumura Y; Okido M; Yamada M; Kai M; Kishimoto J; Miyazaki T; Oda Y; Otsuka T; Nakamura M
PLoS One; 2016; 11(12):e0167016. PubMed ID: 27977696
[TBL] [Abstract][Full Text] [Related]
3. Germline breast cancer susceptibility gene mutations and breast cancer outcomes.
Wang YA; Jian JW; Hung CF; Peng HP; Yang CF; Cheng HS; Yang AS
BMC Cancer; 2018 Mar; 18(1):315. PubMed ID: 29566657
[TBL] [Abstract][Full Text] [Related]
4. BRCAness as a prognostic indicator in patients with early breast cancer.
Liu L; Matsunaga Y; Tsurutani J; Akashi-Tanaka S; Masuda H; Ide Y; Hashimoto R; Inuzuka M; Watanabe C; Taruno K; Sawada T; Okuyama H; Ata A; Kuwayama T; Nakayama S; Tonouchi Y; Nakamura S
Sci Rep; 2020 Dec; 10(1):21173. PubMed ID: 33273622
[TBL] [Abstract][Full Text] [Related]
5. BRCA1 and BRCA2 mutations in ethnic Lebanese Arab women with high hereditary risk breast cancer.
El Saghir NS; Zgheib NK; Assi HA; Khoury KE; Bidet Y; Jaber SM; Charara RN; Farhat RA; Kreidieh FY; Decousus S; Romero P; Nemer GM; Salem Z; Shamseddine A; Tfayli A; Abbas J; Jamali F; Seoud M; Armstrong DK; Bignon YJ; Uhrhammer N
Oncologist; 2015 Apr; 20(4):357-64. PubMed ID: 25777348
[TBL] [Abstract][Full Text] [Related]
6. BRCAness predicts resistance to taxane-containing regimens in triple negative breast cancer during neoadjuvant chemotherapy.
Akashi-Tanaka S; Watanabe C; Takamaru T; Kuwayama T; Ikeda M; Ohyama H; Mori M; Yoshida R; Hashimoto R; Terumasa S; Enokido K; Hirota Y; Okuyama H; Nakamura S
Clin Breast Cancer; 2015 Feb; 15(1):80-5. PubMed ID: 25445419
[TBL] [Abstract][Full Text] [Related]
7. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
Tan DS; Rothermundt C; Thomas K; Bancroft E; Eeles R; Shanley S; Ardern-Jones A; Norman A; Kaye SB; Gore ME
J Clin Oncol; 2008 Dec; 26(34):5530-6. PubMed ID: 18955455
[TBL] [Abstract][Full Text] [Related]
8. BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers.
Vos S; Moelans CB; van Diest PJ
Breast Cancer Res; 2017 May; 19(1):64. PubMed ID: 28569220
[TBL] [Abstract][Full Text] [Related]
9. BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Tanino H; Kosaka Y; Nishimiya H; Tanaka Y; Minatani N; Kikuchi M; Shida A; Waraya M; Katoh H; Enomoto T; Sengoku N; Kajita S; Hoffman RM; Watanabe M
PLoS One; 2016; 11(12):e0165721. PubMed ID: 27935989
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic regulation of ID4 in the determination of the BRCAness phenotype in breast cancer.
Branham MT; Campoy E; Laurito S; Branham R; Urrutia G; Orozco J; Gago F; Urrutia R; Roqué M
Breast Cancer Res Treat; 2016 Jan; 155(1):13-23. PubMed ID: 26610810
[TBL] [Abstract][Full Text] [Related]
11. Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status.
Shah PD; Patil S; Dickler MN; Offit K; Hudis CA; Robson ME
Cancer; 2016 Apr; 122(8):1178-84. PubMed ID: 26859126
[TBL] [Abstract][Full Text] [Related]
12. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations.
Bayraktar S; Gutierrez-Barrera AM; Liu D; Tasbas T; Akar U; Litton JK; Lin E; Albarracin CT; Meric-Bernstam F; Gonzalez-Angulo AM; Hortobagyi GN; Arun BK
Breast Cancer Res Treat; 2011 Nov; 130(1):145-53. PubMed ID: 21830012
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer.
Sønderstrup IMH; Jensen MB; Ejlertsen B; Eriksen JO; Gerdes AM; Kruse TA; Larsen MJ; Thomassen M; Laenkholm AV
Acta Oncol; 2019 Mar; 58(3):363-370. PubMed ID: 30614364
[TBL] [Abstract][Full Text] [Related]
14. Association of BRCA Mutations and BRCAness Status With Anticancer Drug Sensitivities in Triple-Negative Breast Cancer Cell Lines.
Teraoka S; Muguruma M; Takano N; Miyahara K; Kawate T; Kaise H; Yamada K; Miyazawa K; Ishikawa T
J Surg Res; 2020 Jun; 250():200-208. PubMed ID: 32092597
[TBL] [Abstract][Full Text] [Related]
15. Ovarian cancer in BRCA1/2 mutation carriers: The impact of mutation position and family history on the cancer risk.
Teixeira N; Mourits MJ; Vos JR; Kolk DM; Jansen L; Oosterwijk JC; Bock GH
Maturitas; 2015 Oct; 82(2):197-202. PubMed ID: 26239500
[TBL] [Abstract][Full Text] [Related]
16. BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study.
Musolino A; Bella MA; Bortesi B; Michiara M; Naldi N; Zanelli P; Capelletti M; Pezzuolo D; Camisa R; Savi M; Neri TM; Ardizzoni A
Breast; 2007 Jun; 16(3):280-92. PubMed ID: 17257844
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer.
Stadler ZK; Salo-Mullen E; Patil SM; Pietanza MC; Vijai J; Saloustros E; Hansen NA; Kauff ND; Kurtz RC; Kelsen DP; Offit K; Robson ME
Cancer; 2012 Jan; 118(2):493-9. PubMed ID: 21598239
[TBL] [Abstract][Full Text] [Related]
18. Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis.
Sabatier R; Lavit E; Moretta J; Lambaudie E; Noguchi T; Eisinger F; Cherau E; Provansal M; Livon D; Rabayrol L; Popovici C; Charaffe-Jauffret E; Sobol H; Viens P
Fam Cancer; 2016 Oct; 15(4):497-506. PubMed ID: 26833043
[TBL] [Abstract][Full Text] [Related]
19. Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers.
Lips EH; Mulder L; Oonk A; van der Kolk LE; Hogervorst FB; Imholz AL; Wesseling J; Rodenhuis S; Nederlof PM
Br J Cancer; 2013 May; 108(10):2172-7. PubMed ID: 23558900
[TBL] [Abstract][Full Text] [Related]
20. Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel.
Moran O; Nikitina D; Royer R; Poll A; Metcalfe K; Narod SA; Akbari MR; Kotsopoulos J
Breast Cancer Res Treat; 2017 Jan; 161(1):135-142. PubMed ID: 27798748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]